RU2019117556A - Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2 - Google Patents
Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2 Download PDFInfo
- Publication number
- RU2019117556A RU2019117556A RU2019117556A RU2019117556A RU2019117556A RU 2019117556 A RU2019117556 A RU 2019117556A RU 2019117556 A RU2019117556 A RU 2019117556A RU 2019117556 A RU2019117556 A RU 2019117556A RU 2019117556 A RU2019117556 A RU 2019117556A
- Authority
- RU
- Russia
- Prior art keywords
- indazole
- cabroxamide
- fluorophenyl
- chlorophenyl
- alkyl
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 hydroxy, phenyl Chemical group 0.000 claims 181
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 146
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 124
- 125000000217 alkyl group Chemical group 0.000 claims 86
- 125000005842 heteroatom Chemical group 0.000 claims 45
- 229910052760 oxygen Inorganic materials 0.000 claims 45
- 229910052717 sulfur Inorganic materials 0.000 claims 45
- 229910052736 halogen Inorganic materials 0.000 claims 39
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- 125000001072 heteroaryl group Chemical group 0.000 claims 32
- 150000002367 halogens Chemical class 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 28
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 19
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 12
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 201000001320 Atherosclerosis Diseases 0.000 claims 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 claims 1
- 101000930020 Homo sapiens Diacylglycerol O-acyltransferase 2 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- MPGRDAHTZGDVKH-UHFFFAOYSA-N N-(1,1-dioxothiolan-3-yl)-1-(4-fluorophenyl)-3-(1-oxidopyridin-1-ium-3-yl)indazole-6-carboxamide Chemical compound O=S1(CC(CC1)NC(=O)C1=CC=C2C(=NN(C2=C1)C1=CC=C(C=C1)F)C=1C=[N+](C=CC=1)[O-])=O MPGRDAHTZGDVKH-UHFFFAOYSA-N 0.000 claims 1
- PYFKNDZBJPPSIX-UHFFFAOYSA-N [3-(2-chlorophenyl)-1-(4-fluorophenyl)indazol-6-yl]-(3,3-dioxo-3lambda6-thia-6-azabicyclo[3.2.1]octan-6-yl)methanone Chemical compound ClC1=C(C=CC=C1)C1=NN(C2=CC(=CC=C12)C(=O)N1C2CS(CC(C1)C2)(=O)=O)C1=CC=C(C=C1)F PYFKNDZBJPPSIX-UHFFFAOYSA-N 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- HFDSCNFMHXNRDH-UHFFFAOYSA-N ethyl 1-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)indazole-6-carbonyl]amino]cyclopropane-1-carboxylate Chemical compound ClC1=C(C=CC=C1)C1=NN(C2=CC(=CC=C12)C(=O)NC1(CC1)C(=O)OCC)C1=CC=C(C=C1)F HFDSCNFMHXNRDH-UHFFFAOYSA-N 0.000 claims 1
- QYDAVJXXKNPCAX-UHFFFAOYSA-N ethyl 2-[3-(2-chlorophenyl)-6-[(3-methyl-1,1-dioxothiolan-3-yl)carbamoyl]indazol-1-yl]-1,3-oxazole-4-carboxylate Chemical compound ClC1=C(C=CC=C1)C1=NN(C2=CC(=CC=C12)C(NC1(CS(CC1)(=O)=O)C)=O)C=1OC=C(N=1)C(=O)OCC QYDAVJXXKNPCAX-UHFFFAOYSA-N 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- JYMVEPJMPDYEIA-UHFFFAOYSA-N methyl 1-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)indazole-6-carbonyl]amino]cyclopentane-1-carboxylate Chemical compound ClC1=C(C=CC=C1)C1=NN(C2=CC(=CC=C12)C(=O)NC1(CCCC1)C(=O)OC)C1=CC=C(C=C1)F JYMVEPJMPDYEIA-UHFFFAOYSA-N 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims 1
- QWUFVCIGYZDHCD-FQEVSTJZSA-N tert-butyl (3S)-3-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)indazole-6-carbonyl]amino]pyrrolidine-1-carboxylate Chemical compound ClC1=C(C=CC=C1)C1=NN(C2=CC(=CC=C12)C(=O)N[C@@H]1CN(CC1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)F QWUFVCIGYZDHCD-FQEVSTJZSA-N 0.000 claims 1
- WCHZETLLPCMELH-UHFFFAOYSA-N tert-butyl 3-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)indazole-6-carbonyl]amino]propanoate Chemical compound ClC1=C(C=CC=C1)C1=NN(C2=CC(=CC=C12)C(=O)NCCC(=O)OC(C)(C)C)C1=CC=C(C=C1)F WCHZETLLPCMELH-UHFFFAOYSA-N 0.000 claims 1
- VALOLBOVOFJSBX-UHFFFAOYSA-N tert-butyl 4-[1-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)indazole-6-carbonyl]amino]ethyl]imidazole-1-carboxylate Chemical compound ClC1=C(C=CC=C1)C1=NN(C2=CC(=CC=C12)C(=O)NC(C)C=1N=CN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)F VALOLBOVOFJSBX-UHFFFAOYSA-N 0.000 claims 1
- AHIXSNMWCQKTMS-UHFFFAOYSA-N tert-butyl 6-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)indazole-6-carbonyl]amino]-1,1-dioxo-1,4-thiazepane-4-carboxylate Chemical compound ClC1=C(C=CC=C1)C1=NN(C2=CC(=CC=C12)C(=O)NC1CN(CCS(C1)(=O)=O)C(=O)OC(C)(C)C)C1=CC=C(C=C1)F AHIXSNMWCQKTMS-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424066P | 2016-11-18 | 2016-11-18 | |
| US62/424,066 | 2016-11-18 | ||
| PCT/US2017/061223 WO2018093696A1 (en) | 2016-11-18 | 2017-11-13 | Indazole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019117556A true RU2019117556A (ru) | 2020-12-18 |
| RU2019117556A3 RU2019117556A3 (enExample) | 2020-12-18 |
Family
ID=62145755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019117556A RU2019117556A (ru) | 2016-11-18 | 2017-11-13 | Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11104690B2 (enExample) |
| EP (1) | EP3541374A4 (enExample) |
| JP (1) | JP2020502058A (enExample) |
| KR (1) | KR20190078646A (enExample) |
| CN (1) | CN110121341A (enExample) |
| AU (1) | AU2017360939B2 (enExample) |
| BR (1) | BR112019010164A2 (enExample) |
| CA (1) | CA3043203A1 (enExample) |
| MA (1) | MA46856A (enExample) |
| MX (1) | MX2019005786A (enExample) |
| RU (1) | RU2019117556A (enExample) |
| WO (1) | WO2018093696A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| US11787810B2 (en) | 2020-05-18 | 2023-10-17 | Merck Sharp & Dohme Llc | Diacylglyceride O-acyltransferase 2 inhibitors |
| US12410159B2 (en) * | 2020-10-08 | 2025-09-09 | Merck Sharp & Dohme Llc | Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors |
| KR20230084258A (ko) | 2020-10-08 | 2023-06-12 | 머크 샤프 앤드 돔 엘엘씨 | 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 벤즈이미다졸론 유도체의 제조 |
| KR20230124989A (ko) * | 2020-12-22 | 2023-08-28 | 머크 샤프 앤드 돔 엘엘씨 | 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의테트라히드로인다졸 유도체의 제조 |
| KR20240165402A (ko) | 2022-03-23 | 2024-11-22 | 아이디어야 바이오사이언시스 인코포레이티드 | Parg의 억제제로서의 피페라진 치환된 인다졸 화합물 |
| CN120500483A (zh) | 2022-12-02 | 2025-08-15 | 默沙东有限责任公司 | 作为新型二酰基甘油o-酰基转移酶2抑制剂的稠合唑衍生物的制备 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ334213A (en) * | 1996-09-04 | 2000-08-25 | Pfizer | Indazole derivatives as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) for treating asthma, arthritis, bronchitis, CNS disorders |
| ATE253073T1 (de) | 1997-03-07 | 2003-11-15 | Metabasis Therapeutics Inc | Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase |
| WO1998039342A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| EP1112275B9 (en) | 1998-09-09 | 2004-03-10 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| WO2002008188A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| AU2002240235B2 (en) | 2001-01-30 | 2006-07-06 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| WO2003045385A1 (en) * | 2001-11-27 | 2003-06-05 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
| US20090286791A1 (en) | 2001-11-27 | 2009-11-19 | Takeda Pharmaceutical Company Limited | Amide Compounds |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CA2495915A1 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| DK1537078T3 (da) | 2002-08-29 | 2010-08-02 | Merck Sharp & Dohme | Indoler med anti-diabetisk aktivitet |
| US7319170B2 (en) | 2003-01-17 | 2008-01-15 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzensulfonmide derivatives |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| EA200700243A1 (ru) | 2004-07-14 | 2007-08-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения гепатита с |
| ATE531706T1 (de) | 2005-04-30 | 2011-11-15 | Boehringer Ingelheim Int | Neue piperidin-substituierte indole und ihre verwendung als ccr-3-modulatoren |
| WO2007084435A2 (en) | 2006-01-13 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7514433B2 (en) | 2006-08-03 | 2009-04-07 | Hoffmann-La Roche Inc. | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives |
| WO2008088692A2 (en) | 2007-01-12 | 2008-07-24 | Merck & Co., Inc. | Spirochromanon derivatives |
| CA2691010A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
| CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2009042053A2 (en) | 2007-09-21 | 2009-04-02 | Merck & Co., Inc. | Neuromedin u receptor agonists and uses thereof |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| US8461185B2 (en) | 2007-10-31 | 2013-06-11 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| CA2741666C (en) | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| AU2010226829A1 (en) | 2009-03-18 | 2011-09-15 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| US9238647B2 (en) | 2009-03-23 | 2016-01-19 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| EP2410858B1 (en) | 2009-03-23 | 2016-09-07 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
| AU2010229144B2 (en) * | 2009-03-23 | 2012-07-12 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| WO2010118009A1 (en) | 2009-04-06 | 2010-10-14 | Ptc Therapeutics, Inc. | Hcv inhibitor and therapeutic agent combinations |
| WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
| EP3188731B1 (en) | 2014-09-05 | 2019-04-03 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| EP3188732B1 (en) | 2014-09-05 | 2019-07-24 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| EP3188730B1 (en) * | 2014-09-05 | 2019-05-01 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| EP3298001B1 (en) | 2015-05-20 | 2020-05-13 | Eli Lilly and Company | Dgat2 inhibitors |
-
2017
- 2017-11-13 US US16/461,902 patent/US11104690B2/en active Active
- 2017-11-13 AU AU2017360939A patent/AU2017360939B2/en not_active Expired - Fee Related
- 2017-11-13 EP EP17871593.4A patent/EP3541374A4/en active Pending
- 2017-11-13 KR KR1020197016983A patent/KR20190078646A/ko not_active Withdrawn
- 2017-11-13 BR BR112019010164A patent/BR112019010164A2/pt not_active IP Right Cessation
- 2017-11-13 MA MA046856A patent/MA46856A/fr unknown
- 2017-11-13 CA CA3043203A patent/CA3043203A1/en not_active Abandoned
- 2017-11-13 WO PCT/US2017/061223 patent/WO2018093696A1/en not_active Ceased
- 2017-11-13 CN CN201780071343.9A patent/CN110121341A/zh active Pending
- 2017-11-13 RU RU2019117556A patent/RU2019117556A/ru unknown
- 2017-11-13 JP JP2019526217A patent/JP2020502058A/ja not_active Ceased
- 2017-11-13 MX MX2019005786A patent/MX2019005786A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018093696A1 (en) | 2018-05-24 |
| MX2019005786A (es) | 2019-08-26 |
| US20190330239A1 (en) | 2019-10-31 |
| AU2017360939B2 (en) | 2022-03-03 |
| CA3043203A1 (en) | 2018-05-24 |
| US11104690B2 (en) | 2021-08-31 |
| EP3541374A1 (en) | 2019-09-25 |
| KR20190078646A (ko) | 2019-07-04 |
| CN110121341A (zh) | 2019-08-13 |
| EP3541374A4 (en) | 2020-06-10 |
| MA46856A (fr) | 2019-09-25 |
| BR112019010164A2 (pt) | 2019-09-17 |
| RU2019117556A3 (enExample) | 2020-12-18 |
| JP2020502058A (ja) | 2020-01-23 |
| AU2017360939A1 (en) | 2019-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019117556A (ru) | Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2 | |
| RU2017124425A (ru) | Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg | |
| JP2020502058A5 (enExample) | ||
| RU2017125520A (ru) | Соединения, ингибирующие parg | |
| RU2317291C2 (ru) | Производные пиримидина в качестве модуляторов рецептора инсулинподобного фактора роста 1 (igf-1), фармацевтическая композиция, способы получения (варианты) и применение | |
| JP5340177B2 (ja) | 複素環式アスパルチルプロテアーゼ阻害剤 | |
| RU2485114C2 (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| JP5809267B2 (ja) | 血漿カリクレイン阻害剤としてのｎ−（（６−アミノ−ピリジン−３−イル）メチル）−ヘテロアリール−カルボキサミド類 | |
| RU2454405C2 (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
| JP2010533158A5 (enExample) | ||
| RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы | |
| RU2005107463A (ru) | Циклические протеины ингибиторов тирозинкиназы | |
| JP2017500364A5 (enExample) | ||
| JP2013516415A5 (enExample) | ||
| JP2017538750A5 (enExample) | ||
| JP2016523911A5 (enExample) | ||
| JP2019533694A5 (enExample) | ||
| JP2018530591A5 (enExample) | ||
| RU2007117913A (ru) | 2, 6-замещенные-4-монозамещенный амино-пиримидины как антагонисты рецептора простагландина d2 | |
| JP2019518036A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2018145045A (ru) | Соединения бензолсульфонамида и их применение в качестве терапевтических средств | |
| JP2013532713A5 (enExample) | ||
| RU2013113118A (ru) | Гетероарилметиламиды | |
| RU2019132212A (ru) | Селективные ингибиторы hdac6 |